BRCA1 is a well-studied tumor suppressor involved in the homologous repair of DNA damage, whereas PINK1, a mitochondrial serine/threonine kinase, is known to be involved in mitochondrial quality control. Genetic mutations of PINK1 and Parkin cause autosomal recessive early-onset Parkinson’s disease. We found that in breast cancer cells, the mitochondrial targeting reagents, which all induce mitochondrial depolarization along with PINK1 upregulation, induced proteasomal BRCA1 degradation. This BRCA1 degradation was dependent on PINK1, and BRCA1 downregulation upon mitochondrial damage caused DNA double-strand breaks. BRCA1 degradation was mediated through the direct interaction with the E3 ligase Parkin. Strikingly, BRCA1 and PINK1/Parkin expression were inversely correlated in cancerous mammary glands from breast cancer patients. BRCA1 knockdown repressed cancer cell growth, and high BRCA1 expression predicted poor relapse-free survival in breast cancer patients. These observations indicate a novel mechanism by which mitochondrial damage is transmitted to the nucleus, leading to BRCA1 degradation.
BRCA1 degradation in response to mitochondrial damage in breast cancer cells
Kana Miyahara,Naoharu Takano,Yumiko Yamada,Hiromi Kazama,Mayumi Tokuhisa,Hirotsugu Hino,Koji Fujita,E. Barroga,M. Hiramoto,H. Handa,M. Kuroda,T. Ishikawa,K. Miyazawa
Published 2021 in Scientific Reports
ABSTRACT
PUBLICATION RECORD
- Publication year
2021
- Venue
Scientific Reports
- Publication date
2021-04-22
- Fields of study
Biology, Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-53 of 53 references · Page 1 of 1
CITED BY
Showing 1-16 of 16 citing papers · Page 1 of 1